GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abliva AB (OTCPK:NEVPF) » Definitions » Net Income (Continuing Operations)

NEVPF (Abliva AB) Net Income (Continuing Operations) : $-8.57 Mil (TTM As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Abliva AB Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Abliva AB's Net Income (Continuing Operations) for the three months ended in Sep. 2024 was $-1.91 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2024 was $-8.57 Mil.


Abliva AB Net Income (Continuing Operations) Historical Data

The historical data trend for Abliva AB's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abliva AB Net Income (Continuing Operations) Chart

Abliva AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.16 -7.17 -13.59 -8.22 -9.31

Abliva AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.97 -2.46 -1.75 -2.46 -1.91

Abliva AB Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abliva AB  (OTCPK:NEVPF) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.


Abliva AB Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Abliva AB's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


Abliva AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abliva AB (OTCPK:NEVPF) » Definitions » Net Income (Continuing Operations)
Traded in Other Exchanges
Address
Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase. . The company is focused on two projects. KL1333, a powerful NAD+ and NADH regulator, in late-stage development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement therapy, has just completed preclinical development.